NEW YORK–(BUSINESS WIRE)–October 30, 2023–
The medical community’s understanding of the endocannabinoid system (ECS) has been greatly improved with the launch of American Journal of Endocannabinoid Medicine (AJEM). AJEM has become the leading resource for healthcare professionals seeking comprehensive, high-level information on the complex world of ECS.
Healthcare providers, particularly physicians and medical professionals, are increasingly recognizing the importance of the endocannabinoid system to human health. The ECS plays a central role in the regulation of a wide range of physiological processes, making it a subject of immense importance in modern medicine. Therapies that interact with the ECS, including cannabinoid and psychedelic medications, have enormous potential in treating a range of conditions and diseases.
THE AJEM The online platform has been meticulously designed to meet the high-level information needs of healthcare professionals. It provides a wealth of resources, including original peer-reviewed research articles, expert analyses, and AJEM Live video and podcast interviews, all aimed at expanding the knowledge base of medical practitioners in the field of endocannabinoid medicine .
Main features of the AJEM Online platform:
Cutting-edge research: AJEM provides access to the latest research results and advances in the study of ECS. Healthcare professionals can stay abreast of the latest developments in this rapidly evolving field.
Peer-reviewed content: all articles published on AJEM are subject to rigorous peer review, ensuring the highest standards of accuracy and credibility.
Clinical Insights: The website includes clinical case studies and expert opinions to help healthcare providers apply ECS knowledge in real-world medical scenarios.
Multidisciplinary approach: AJEM promotes collaboration across diverse medical disciplines, bringing together experts from diverse backgrounds to provide a holistic view of endocannabinoid medicine.
Educational Resources: In addition to research articles, the website offers educational materials, webinars, and resources to facilitate the continuing education of healthcare professionals.
As the medical community increasingly recognizes the therapeutic potential of cannabinoid and psychedelic medications, AJEM stands out as an indispensable resource for healthcare professionals looking for an authoritative source of information about ECS.
About AJEM:
THE American Journal of Endocannabinoid Medicine ( AJEM ) is the leading online platform dedicated to educating healthcare professionals on medications that interact with the endocannabinoid system (ECS). By presenting clinical research on the ECS as a therapeutic target AJEM seeks to improve the practice of evidence-based cannabinoid and psychedelic medicine. AJEM publishes original peer-reviewed research manuscripts and interpretations of research, news and opinion articles written by thought leaders in the field. AJEM Renowned editorial board members participate in the peer review process and constitute a diverse group of experts with experience in various disciplines of cannabinoid medicine. To learn more, visit www.endocannabinoidmedicine.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20231030558127/en/
CONTACT: For inquiries, further information or media requests, please contact: Ken Watkins, Brand Director
ken.watkins@haymarketmedia.comMeg Block Roloff, MPH, Senior Editor
megan.roloff@haymarketmedia.comLeslie Apgar, MD, Editor-in-Chief
leslie.apgar-ext@haymarketmedia.comTracie Palmer, Senior Director, Marketing and Public
tracie.palmer@haymarketmedia.com
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
KEYWORD INDUSTRY: RESEARCH CANNABIS OTHER HEALTH ALTERNATIVE MEDICINE PHARMACEUTICAL HEALTH GENERAL HEALTH SCIENCE NATURAL RESOURCES
SOURCE: American Journal of Endocannabinoid Medicine
Copyright Business Wire 2023.
ADVERTISING: 10/30/2023 3:40 p.m./DISC: 10/30/2023 3:39 p.m.
Copyright Business Wire 2023.
